It can assess patients’ suitability for Amgen’s colorectal cancer drug, Vectibix. Canadian regulatory authorities approved DxS’ TheraScreen K-RAS Mutation Kit for use as a diagnostic for anti-EGFR ...
QIAGEN (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) today announced the regulatory approval of its therascreen ® EGFR Mutation Detection Kit RGQ in Japan. EGFR, the epidermal growth factor receptor, ...
Testing for genetic mutations has long been complicated, expensive, time-consuming, and, in some parts of the world, inaccessible. Dr. Pierre Billon, an assistant professor at the University of ...
Assures 100x upgraded detection sensitivity compare to ddPCR Higher the possibility of precision medicine in the 1st and 2nd stages of cancer patients SEOUL, South Korea--(BUSINESS WIRE)--GENECAST, ...
Dublin, Oct. 14, 2025 (GLOBE NEWSWIRE) -- The "Mutation Detection Kits in Genome Editing Market Report 2025" has been added to ResearchAndMarkets.com's offering. The mutation detection kits in the ...
The APIS ESR1 Mutations Kit is an advanced qPCR assay for the detection of mutations within the estrogen receptor gene. The ESR1 Mutations Kit is described by the company as a qualitative test, ...
DxS has announced that lung cancer patients who have acquired gene mutations associated with resistance to tyrosine kinase inhibitors such as Iressa or Tarceva can be identified accurately using a ...
Researchers working on an incurable blood cancer can now use a new lab model that could make testing potential new treatments and diagnostics easier and quicker, new research has found. Subscribe to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback